Evaluation of risk factors for intravenous colistin use-related nephrotoxicity

Oman Medical Journal

Volumn 31, Issue 4, 2016, Pages 318-321

  Koksal, Iftihar ^a   Kaya, Selcuk ^a   Gencalioglu, Eda ^a   Yilmaz, Gurdal ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Colistin; Renal insufficiency; Risk factors

Indexed keywords

COLISTIN; CREATININE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG SAFETY; DRUG USE; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84983086767     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2016.62     Document Type: Article

References (21)

1. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011 Nov; 53(9): 879-884.
2. Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 2015 Jan; 35(1): 28-33.
3. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: An update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 2012 Aug; 10(8): 917-934.
4. Amsden GW. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin RL, Blaser M, editors. Principles and Practice of Infectious Diseases. Elsevier; 2014.
5. Bennett JE, Dolin R, Blaser MJ. Practice of Infectious Disease. In: Mandell GL, Douglas RG, Bennett JE, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease. Philadelphia: Churchill-Livingstone; 2010. p.705-761.
6. Zorgani A, Abofayed A, Glia A, Albarbar A, Hanish S. Prevalence of Device-associated Nosocomial Infections Caused By Gram-negative Bacteria in a Trauma Intensive Care Unit in Libya. Oman Med J 2015 Jul; 30(4): 270-275.
7. Pike M, Saltiel E. Colistin- and polymyxin-induced nephrotoxicity: Focus on literature utilizing the RIFLE classification scheme of acute kidney injury. J Pharm Pract 2014 Dec; 27(6): 554-561.
8. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013 Nov; 57(9): 1300-1303.
9. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014 Apr; 43(4): 349-352.
10. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011 Jul; 55(7): 3284-3294.
11. Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012 Jul; 65(1): 80-87.
12. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010 Oct; 54(10): 4503-4505.
13. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009 Jun; 48(12): 1724-1728.
14. Kwon JA, Lee JE, Huh W, Peck KR, Kim YG, Kim DJ, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010 May; 35(5): 473-477.
15. Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: A prospective observational cohort study. BMC Infect Dis 2013; 13: 380.
16. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012 May; 56(5): 2392-2396.
17. Ko HJ, Jeon MH, Choo EJ, Lee EJ, Kim TH, Jun JB, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011; 117(3): c284-c288.
18. Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy 2013 Aug; 33(8): 812-816.
19. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011 Dec; 31(12): 1257-1264.
20. Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: Implications for dosing regimen design. Antimicrob Agents Chemother 2012 Sep; 56(9): 4625-4629.
21. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010 Oct; 65(10): 2231-2237.